DDInter336 DDInter1269
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.
Celecoxib {u} (Compound) binds {v} (Gene) ORM1
ORM1 {u} (Gene) is bound by {v} (Compound) Nateglinide
Celecoxib {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Celecoxib {u} (Compound) binds {v} (Gene) ORM1
ORM1 {u} (Gene) interacts with {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Nateglinide
Celecoxib {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Nateglinide
Celecoxib {u} (Compound) binds {v} (Gene) ABCC4
ABCC4 {u} (Gene) is bound by {v} (Compound) Sulfinpyrazone
Sulfinpyrazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nateglinide
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Celecoxib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Amphetamine
Amphetamine {u} (Compound) resembles {v} (Compound) Nateglinide
Celecoxib {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Amphetamine
Amphetamine {u} (Compound) resembles {v} (Compound) Nateglinide
Celecoxib {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Nateglinide
Celecoxib {u} (Compound) causes {v} (Side Effect) Back pain
Back pain {u} (Side Effect) is caused by {v} (Compound) Enalapril
Enalapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Celecoxib (Compound) binds ORM1 (Gene) and ORM1 (Gene) is bound by Nateglinide (Compound)
Celecoxib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Celecoxib (Compound) binds ORM1 (Gene) and ORM1 (Gene) interacts with ALB (Gene) and ALB (Gene) is bound by Nateglinide (Compound)
Celecoxib (Compound) binds ALB (Gene) and ALB (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Nateglinide (Compound)
Celecoxib (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Nateglinide
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Celecoxib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Amphetamine (Compound) and Amphetamine (Compound) resembles Nateglinide (Compound)
Celecoxib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Amphetamine (Compound) and Amphetamine (Compound) resembles Nateglinide (Compound)
Celecoxib (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Ramipril (Compound) and Ramipril (Compound) resembles Nateglinide (Compound)
Celecoxib (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide